galantamine has been researched along with Parkinson Disease in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (55.56) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Aktumsek, A; Alcaro, S; Bagetta, D; Carradori, S; De Monte, C; De Vita, D; Guglielmi, P; Ortuso, F; Petzer, A; Petzer, JP; Secci, D; Zengin, G | 1 |
| Achten, E; Beun, S; Clement, P; Moyaert, P | 1 |
| Algharably, EEA; Bermpohl, F; Bittner, N; Brandl, EJ; Funk, CSM; Kreutz, R; Riemer, TG; Schmidt, A | 1 |
| Chukhlovina, ML | 1 |
| Lewis, SJ; Szeto, JY | 1 |
| Amick, MM; Friedman, JH; Grace, J | 1 |
| Emelin, AY; Litvinenko, IV; Mogil'naya, VI; Odinak, MM | 1 |
| Krasakov, IV; Litvinenko, IV; Tikhomirova, OV | 1 |
| Khaĭmov, DA; Khalimov, RR; Krasakov, IV; Litvinenko, IV; Trufanov, AG | 1 |
| Aarsland, D; Hutchinson, M; Larsen, JP | 1 |
| Becher, PG; Beuchat, J; Gademann, K; Jüttner, F | 1 |
| Cummings, JL; Ringman, JM | 1 |
| Johannsen, P | 1 |
| Gallini, A; Montastruc, JL; Salandini, AM; Sommet, A; Veyssière, P | 1 |
| Anghelescu, I; Heuser, I | 1 |
| Emelin, AIu; Litvinenko, IV; Mogil'naia, VI; Odinak, MM | 1 |
| Kamenetskiĭ, VK; Losev, NA | 1 |
7 review(s) available for galantamine and Parkinson Disease
| Article | Year |
|---|---|
Effect of Acetylcholinesterase Inhibitors on Cerebral Perfusion and Cognition: A Systematic Review.
Topics: Acetylcholinesterase; Alzheimer Disease; Cerebrovascular Circulation; Cholinesterase Inhibitors; Cognition; Dementia; Galantamine; Humans; Indans; Parkinson Disease; Perfusion; Phenylcarbamates; Piperidines; Rivastigmine | 2023 |
Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer's Disease and Parkinson's Dementia: Systematic Review and Meta-Analysis.
Topics: Acetylcholinesterase; Alzheimer Disease; Anorexia; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Parkinson Disease; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine; Sleep Initiation and Maintenance Disorders | 2023 |
[Pathogenetic mechanisms of dementia in the older patients with Parkinson's diseases].
Topics: Aging; alpha-Synuclein; Aminoquinolines; Cholinergic Neurons; Cholinesterase Inhibitors; Dementia; Female; Galantamine; Humans; Male; Mutation; Parkinson Disease; Phenylcarbamates; Protein Kinases; Rivastigmine | 2014 |
Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Cognitive Behavioral Therapy; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Exercise Therapy; Galantamine; Humans; Indans; Memantine; Parkinson Disease; Piperidines; Rivastigmine; Sleep Wake Disorders; Treatment Outcome | 2016 |
Current and emerging pharmacological treatment options for dementia.
Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans; Indans; Lewy Body Disease; Neurodegenerative Diseases; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2006 |
[Medical treatment of Alzheimer's disease].
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Dementia, Vascular; Disease Progression; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Lewy Body Disease; Memantine; Nootropic Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2006 |
[Acetylcholinesterase inhibitors for dementia--an update].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia; Donepezil; Galantamine; Humans; Indans; Lewy Body Disease; Multicenter Studies as Topic; Neuroprotective Agents; Nootropic Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Time Factors | 2007 |
5 trial(s) available for galantamine and Parkinson Disease
| Article | Year |
|---|---|
A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease.
Topics: Aged; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Double-Blind Method; Female; Galantamine; Humans; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Placebos; Quality of Life; Treatment Outcome | 2009 |
Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial).
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Caregivers; Cholinesterase Inhibitors; Cognition; Dementia; Family; Galantamine; Humans; Mental Status Schedule; Middle Aged; Motor Activity; Parkinson Disease; Severity of Illness Index; Time Factors | 2008 |
[New approach to gait disorders therapy in late stages of Parkinson's disease].
Topics: Aged; Biological Availability; Cholinesterase Inhibitors; Cognition Disorders; Combined Modality Therapy; Female; Gait; Gait Disorders, Neurologic; Galantamine; Humans; Male; Middle Aged; Monitoring, Physiologic; Neuropsychological Tests; Parkinson Disease; Psychiatric Status Rating Scales; Severity of Illness Index; Synaptic Transmission; Transcranial Magnetic Stimulation; Treatment Outcome | 2012 |
Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia.
Topics: Aged; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Female; Galantamine; Hallucinations; Humans; Male; Mental Status Schedule; Nootropic Agents; Parkinson Disease; Treatment Outcome | 2003 |
[Efficacy and safety of galantamine (reminyl) in the treatment of dementia in patients with Parkinson's disease (open-label controlled trial)].
Topics: Aged; Cognition; Dementia; Dose-Response Relationship, Drug; Follow-Up Studies; Galantamine; Humans; Motor Activity; Nootropic Agents; Parkinson Disease; Quality of Life; Severity of Illness Index; Time Factors; Treatment Outcome | 2007 |
6 other study(ies) available for galantamine and Parkinson Disease
| Article | Year |
|---|---|
Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents.
Topics: Acetylcholinesterase; Animals; Antioxidants; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Electrophorus; Horses; Humans; Hydrazones; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Structure-Activity Relationship | 2018 |
[Sleep disorders in patients with dementia in Parkinson's disease].
Topics: Aged; Dementia; Female; Galantamine; Humans; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Sleep Wake Disorders; Sleep, REM | 2011 |
Nostocarboline: isolation and synthesis of a new cholinesterase inhibitor from Nostoc 78-12A.
Topics: Brain; Butyrylcholinesterase; Carbolines; Cholinesterase Inhibitors; Galantamine; Humans; Inhibitory Concentration 50; Molecular Structure; Nostoc; Parkinson Disease | 2005 |
Weight-loss associated with anti-dementia drugs in a patient with Parkinson's disease.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Anorexia; Antiparkinson Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Galantamine; Humans; Lewy Body Disease; Memantine; Mental Status Schedule; Nausea; Nootropic Agents; Parkinson Disease; Vomiting; Weight Loss | 2007 |
Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Dystonia; France; Galantamine; Humans; Indans; Lewy Body Disease; Parkinson Disease; Phenylcarbamates; Piperidines; Tremor | 2007 |
[Method of treating parkinsonism with metamizil in combination with galanthamine (clinico-experimental basis)].
Topics: Aged; Animals; Benactyzine; Brain; Drug Therapy, Combination; Galantamine; Humans; Male; Mice; Middle Aged; Parkinson Disease; Receptors, Muscarinic; Receptors, Nicotinic | 1985 |